“…Knockdown of Angpt2 in hepatoma cells abolishes VETC formation and, in turn, reduces the in vivo metastasis of HCC xenografts . These findings indicate VETC as a novel target for antimetastasis therapy, and highlight the need to identify the molecules that regulate the VETC pattern . However, the regulatory mechanisms of VETC formation in HCC remain unexplored.…”
“…Knockdown of Angpt2 in hepatoma cells abolishes VETC formation and, in turn, reduces the in vivo metastasis of HCC xenografts . These findings indicate VETC as a novel target for antimetastasis therapy, and highlight the need to identify the molecules that regulate the VETC pattern . However, the regulatory mechanisms of VETC formation in HCC remain unexplored.…”
“…Sorafenib (Nexavar ® ) and Lenvatinib (Lenvima ® ), two multi-kinase inhibitors with potent anti-angiogenic capacity, have been used as first-line therapies for hepatocellular carcinoma in the past [ 23 , 24 ]. The VETC pattern used has also been shown to be a predictive biomarker for sorafenib treatment efficacy [ 13 , 14 , 15 ].…”
Section: Discussionmentioning
confidence: 99%
“…Angiogenesis is important for both tumor growth and metastases in HCC, and this can be identified using the intra-tumoral microvessel density (MVD) [ 11 , 12 ]. Vessels that encapsulate tumor clusters (VETC) are another specific tumor vascular pattern that has been reported recently [ 13 , 14 , 15 ]. Microscopically, each tumor cluster is encapsulated by sinusoid-like vessels that form cobweb-like networks [ 16 ].…”
Section: Introductionmentioning
confidence: 99%
“…Microscopically, each tumor cluster is encapsulated by sinusoid-like vessels that form cobweb-like networks [ 16 ]. Knockdown of angiopoietin-2 (Ang2) could reduce the vascular pattern and decrease in vivo metastasis [ 13 ]. Fang and Xu et al reported that the VETC pattern in patients with HCC is a predictor of beneficial effects in sorafenib treatment, and that this may be related to its antagonistic effect on Ang2 [ 14 ].…”
The outcomes of patients with hepatocellular carcinoma (HCC) are unsatisfactory because of its high recurrence rate. The Vessels that encapsulate tumor clusters (VETC) pattern is a unique vascular structure. In this study, we investigated the clinical–pathological features of HCC patients with the VETC pattern. We retrospectively reviewed patients with HCC who underwent curative hepatectomy at Chang Gung Memorial Hospital between 2007 and 2013. The form of the VETC pattern was established using an anti-CD31 stain. The results were classified into positive (VETC+) and negative (VETC−) patterns. We investigated and compared demographic data between these two groups. Overall, 174 patients were classified into either the VETC+ or VETC− groups. The median followed-up period was 80.5 months. There were significant differences in the number of hepatitis B carriers, the occurrence of vascular invasion, tumor size, TNM staging, microvessel density, and recurrence (all p < 0.05). Regarding the prediction of disease-free survival, after COX regression multivariate analysis, VETC+ remained independently associated with recurrent episodes (p = 0.003). The intra-tumoral microvessel density, demonstrated by CD-31, was the only clinical–pathological feature independently associated with VETC+. Our study demonstrated that the VETC pattern is an independent factor of poor prognosis for DFS. Higher intra-tumoral microvessel density was significantly associated with the VETC pattern. Further studies are needed to validate our findings.
“…Surgical resection is still regarded as the first choice of HCC treatment [8][9][10][11][12] . However, due to intrahepatic metastasis and early recurrence, postoperative patients' prognosis is poor [13][14][15][16][17][18] , and the 5-year survival rate is relatively low [19] . The high recurrence and vascular invasion of HCC limit the long-term survival of HCC patients.…”
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer-related death worldwide. Surgical resection is still regarded as the first choice of treatment for HCC. With advances in technology and techniques, minimally invasive surgery has now become the standard of care in almost every field in general surgery, including hepatectomy surgery. This review focuses on the latest advances in minimally invasive surgical treatment of HCC, including laparoscopic hepatectomy (LH), robotic hepatectomy (RH) and other minimally invasive treatment technologies. Although some limitation in LH or RH exists, these minimally invasive techniques may be performed for hepatectomy with benefits, and have a promising future. With the development of technology and the improvement of surgical operations, patients will benefit from this.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.